FY2024 EPS Estimates for Ikena Oncology Increased by Analyst

Ikena Oncology, Inc. (NASDAQ:IKNA) – Research analysts at HC Wainwright increased their FY2024 earnings per share (EPS) estimates for Ikena Oncology in a report issued on Monday, November 11th. HC Wainwright analyst A. Maldonado now anticipates that the company will post earnings of ($0.95) per share for the year, up from their prior forecast of ($1.07). HC Wainwright has a “Buy” rating and a $4.00 price objective on the stock. The consensus estimate for Ikena Oncology’s current full-year earnings is ($0.95) per share. HC Wainwright also issued estimates for Ikena Oncology’s Q4 2024 earnings at ($0.20) EPS, Q1 2025 earnings at ($0.20) EPS, Q2 2025 earnings at ($0.20) EPS, Q3 2025 earnings at ($0.20) EPS, Q4 2025 earnings at ($0.20) EPS, FY2025 earnings at ($0.81) EPS, FY2026 earnings at ($0.95) EPS, FY2027 earnings at ($0.93) EPS and FY2028 earnings at ($0.70) EPS.

Separately, Wedbush reaffirmed a “neutral” rating and issued a $2.00 price objective on shares of Ikena Oncology in a report on Thursday, November 7th.

Ikena Oncology Stock Performance

IKNA stock opened at $1.71 on Thursday. Ikena Oncology has a 1 year low of $1.22 and a 1 year high of $2.32. The stock has a market capitalization of $82.52 million, a price-to-earnings ratio of -1.41 and a beta of 0.48. The stock’s fifty day moving average is $1.71 and its two-hundred day moving average is $1.65.

Ikena Oncology (NASDAQ:IKNA) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.08.

Hedge Funds Weigh In On Ikena Oncology

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Jacobs Levy Equity Management Inc. boosted its position in Ikena Oncology by 813.7% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 513,440 shares of the company’s stock worth $729,000 after acquiring an additional 457,245 shares during the period. Sofinnova Investments Inc. raised its stake in shares of Ikena Oncology by 230.7% during the second quarter. Sofinnova Investments Inc. now owns 382,616 shares of the company’s stock valued at $631,000 after purchasing an additional 266,904 shares in the last quarter. Acadian Asset Management LLC lifted its holdings in Ikena Oncology by 1,201.8% in the first quarter. Acadian Asset Management LLC now owns 282,782 shares of the company’s stock worth $400,000 after purchasing an additional 261,060 shares during the period. Blue Owl Capital Holdings LP grew its position in Ikena Oncology by 5.1% in the 2nd quarter. Blue Owl Capital Holdings LP now owns 4,091,118 shares of the company’s stock valued at $6,750,000 after buying an additional 200,000 shares in the last quarter. Finally, BML Capital Management LLC increased its stake in Ikena Oncology by 23.6% during the 3rd quarter. BML Capital Management LLC now owns 723,288 shares of the company’s stock valued at $1,251,000 after buying an additional 138,174 shares during the period. 75.00% of the stock is owned by institutional investors.

Ikena Oncology Company Profile

Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.